# Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

> **NCT04855656** · PHASE1 · RECRUITING · sponsor: **Debiopharm International SA** · enrollment: 464 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Lunresertib
- **DRUG:** RP-3500
- **DRUG:** Debio0123

## Key facts

- **NCT ID:** NCT04855656
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-30
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 464 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855656, "Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04855656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*